Shift Bioscience, a biotech company focused on using AI technology to combat age-related diseases, has announced the establishment of a new team and facilities in North America. The team, based in Toronto, Canada, will be led by Lucas Camillo as Head of Machine Learning, with Professor Bo Wang serving as Senior Advisor. This move comes after the company’s successful $16 M Seed funding round in October 2024 and aims to leverage the region’s top machine learning talent to strengthen the company’s virtual cell platform.
North America, known for its expertise in AI and machine learning, is a strategic location for Shift Bioscience as it looks to expand its capabilities and enhance its IP portfolio. The team in Toronto will focus on exploring new capabilities for the virtual cell platform and identifying rejuvenation gene targets with the guidance of Professor Bo Wang, an expert in AI and computational biology.
Lucas Camillo emphasized the importance of accessing the region’s talent pool and expressed excitement about working with Professor Bo Wang to build a strong team and continue developing the virtual cell platform. Professor Bo Wang, on the other hand, highlighted the potential of Shift Bioscience’s technology to address age-related diseases and expressed eagerness to contribute his expertise in cell simulation to accelerate development.
With a focus on leveraging AI technology to unlock new gene targets and improve patient care, Shift Bioscience’s move to establish a team in North America marks a significant step in advancing their mission of combating age-related diseases.
Note: The image is for illustrative purposes only and is not the original image associated with the presented article. Due to copyright reasons, we are unable to use the original images. However, you can still enjoy the accurate and up-to-date content and information provided.
